Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology

Eitemau Tebyg

• Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology
  gan: Lindeman, Neal I., et al.
  Cyhoeddwyd: (2013)
• Impact of the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology clinical practice guidelines for EGFR and ALK testing in lung cancer in Canada
  gan: Ionescu, D.N.
  Cyhoeddwyd: (2013)
• ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma
  gan: Dacic, Sanja, et al.
  Cyhoeddwyd: (2016)
• Histopathologic and molecular approach to staging of multiple lung nodules
  gan: Schneider, Frank, et al.
  Cyhoeddwyd: (2017)
• EMT is associated with, but does not drive resistance to ALK inhibitors among EML4‐ALK non‐small cell lung cancer
  gan: Gower, Arjan, et al.
  Cyhoeddwyd: (2015)